Janssen Search
Search results
Clinical Trials: Against All Odds
A Janssen leader’s reflections on 'Clinical Trials: Against All Odds' Clinical trials are a hugely complex enterprise that depend on the expertise, organization and dedication of many scientists, engineers, clinicians, project managers and ...
We Need a 'Surge' in RSV Awareness
We Need a 'Surge' in RSV Awareness COVID-19 has been an ever-present part of our lives since 2020 and has altered nearly all the ways in which we interact with the world and with one another. The pandemic has also led to an overall increase in ...
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible
Jul 30, 2024 Findings from first-ever quadruplet therapy study with subcutaneous DARZALEX FASPRO® showed 60 percent reduction in risk of disease progression or death New regimen solidifies DARZALEX FASPRO ® as a foundational frontline therapy in multiple ...
Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen for treatment of patients with transplant-eligible, newly diagnosed multiple myeloma
Jan 30, 2024 United States Data supporting the application showed the addition of DARZALEX FASPRO ® to lenalidomide, bortezomib and dexamethasone (VRd) induction and consolidation and lenalidomide maintenance therapy reduced the risk of progression or ...
Increasing Sustainable Access to Medicines
Increasing Sustainable Access to Medicines Janssen, as part of its commitment to Global Public Health, cultivates and helps implement innovative pricing and results-based financing models that improve access to our medicines for patients in resource ...
Three Things to Know When Initiating Treatment With a Biologic
Three Things to Know When Initiating Treatment With a Biologic As a former practicing physician, I know that patients can sometimes feel overwhelmed when navigating a new treatment. With multiple stakeholders on the journey to accessing a biologic drug ...
Dr. Paul Stoffels Reflects On The Progress We Have Made Against HIV
Dr. Paul Stoffels Reflects on the Progress We Have Made Against HIV Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson, has spent much of his career fighting AIDS. To mark World AIDS Day (Dec. 1, 2016) our colleagues at Johnson & ...
BeneVir’s Oncolytic Virus Technology Offers a Unique Opportunity to Strengthen Janssen’s Immunotherapy Research
BeneVir’s Oncolytic Virus Technology Offers a Unique Opportunity to Strengthen Janssen’s Immunotherapy Research Nov 20, 2018 At a small company in Rockville, Maryland, a handful of researchers are working on viruses that can be tailored to avoid ...
The New Science of Cancer Interception
Thwarting Deadly Diseases Before They Start: The New Science of Cancer Interception Imagine if your doctor could detect cancer before it began growing in your body, then give you medicine to prevent it from taking hold. This researcher explains how she ...
Championing Patient-Centric, Data-Driven Clinical Trials
Championing Patient-Centric, Data-Driven Clinical Trials The Question that Drives Clinical Trial Innovation One common question I receive as Janssen Clinical Innovation’s Global Team Lead is, “what will clinical trials look like in five years, 10 ...